| 期刊全称 | Biomarkers for Huntington‘s Disease | | 期刊简称 | Improving Clinical O | | 影响因子2023 | Elizabeth A. Thomas,Georgia M. Parkin | | 视频video | | | 发行地址 | Presents the latest advances in the development of digital biomarkers for use in Huntington’s disease.Reviews the current status of fluid biomarkers for Huntington‘s disease.Explores the function of b | | 学科分类 | Contemporary Clinical Neuroscience | | 图书封面 |  | | 影响因子 | Huntington’s disease (HD) is a fatal, inherited, neurodegenerative disorder, characterized by chorea, motor instabilities, psychiatric manifestations and cognitive decline. Early genetic testing provides an opportunity for clinical interventions aimed at delaying onset and/or slowing progression of disease; however, current treatments for HD are limited, with only two FDA-approved drugs available to manage chorea. Encouragingly, however, several disease-modifying treatment approaches are in the therapeutic pipeline, with more than 200 clinical studies, and many more preclinical studies, in the works. Robust and reliable biomarkers are needed to predict disease onset, monitor disease progression and assess treatment responses. More specifically, biomarkers to stratify patients for clinical trials and biomarkers to track drug efficacy will certainly lead to improved clinical trial design and success. This book represents the first book focused solely on biomarkers for HD and represents adistinct resource that will be informative, not only for clinicians and those involved in clinical trial design, but also for a wide range of neurodegenerative disease researchers. This edited volume | | Pindex | Book 2023 |
The information of publication is updating
|
|
发表于 2025-3-21 17:50:24
